Treatment of refractory erythroderma with apremilast
DOI:
https://doi.org/10.66344/jpad.34.1.2024.2454Keywords:
Erythroderma, Psoriasis, ApremilastAbstract
Erythroderma is an exfoliative dermatitis with erythema involving more than 90% of body surface area. It has many causes which should be ruled out to confirm diagnosis. Apremilast is an inhibitor of phosphodiesterase 4 (PDE-4) which targets intracellularly cascade for anti-inflammatory effect. Here, we present a case of 55years old male in erythroderma with history of psoriasis who did not respond to conventional treatment of psoriatic erythroderma with phototherapy, methotrexate and acetretin but underwent almost complete remission after apremilast treatment.References
Rothe MJ, Bernstein ML, Grant-kels JM. Life threatening erythroderma: diagnosing and treating the “red man†Clin dermatol. 2005;23:206-217. doi: 10.1016/j.clindermatol.2004.06.018. [PubMed][CrossRef][Google Scholar]
Mistry N, Gupta A, Alva A, Sibbald G. A review of the diagnosis and Management of Erythroderma (generalized red skin). In: Advance in skin and wound care: Woltker Kluwer Health; 2015.p.228-36. www.woundcarejournal.com. [PubMed]
Caher JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol. 2014;15(6):467-478. Doi: 10.1007/s40257-014-0097-1. [PMC free article][PubMed][CrossRef][google Scholar]
Tiago Torres, Luis Puig. Apremilast : a novel oral treatment for psoriasis and psoriatic arthritis. American Journal of clinical dermatology. (2018). 19(1), 23-32,2018. [PubMed][CrossRef][google Scholar]
Nicolla Balato, Luisa DI Costanzo and Anna Balato. Differential diagnosis of psoriasis.The joural of rheumatology supplement August 2009,83 24-25;DOI://doi.org/10.3899/jrheum.090216
Carlo pincelli, pater H Schafer, Lars E French, Matthias Augustin, james G Krueger. Mechanism of underlying the clinical effects of apremilast for psoriasis. Journal of drugs in dermatology: JDD 17(8), 835-840, 2018
Celgene Corporation Oral Otezla (apremilast) approved by U.S Food and Drug Administration for the treatment of patients with moderate to severe plaque psoriasis. Sep 23,2014. http://ir.celgene.com/releasedetail.cfm . accessed July 6,2015.
F. Amatore, A P Villani, M tauber, M Viguire, B Guillot. French guidelines on the use of systemic treatments for moderate to severe psoriasis in adults. Journal of European academy of dermatology and venereology/volume33, issue 3/p.464-483. Published : 22 february 2019. http//doi.org/10.1111/jdv.15340
Celgene corporation. Product monograph 2017: otezle(apremilast) tablets 10mgmg, 20 mg, and 30 mg. available from: http://media.celgene.com/content/uploads/sites/23/otezla-product-monograph-english.pdf
Annia Langley, Jannifer Beecker. Management of common side effects of apremilast. Journal of cutaneous medicine and surgery. 22(4), 415-421,2017. http://doi.org/10.1177/1203475417748886.
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
